

AD _____

GRANT NUMBER DAMD17-96-1-6170

TITLE: Use of p53 Mutation Analysis for Staging Breast Cancer

PRINCIPAL INVESTIGATOR: Marga White, Ph.D.

CONTRACTING ORGANIZATION: Oncormed, Incorporated
Gaithersburg, Maryland 20877

REPORT DATE: August 1998

TYPE OF REPORT: Final

PREPARED FOR: Commanding General
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION AGREEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE August 1998	3. REPORT TYPE AND DATES COVERED Final (1 Aug 96 - 31 Jul 98)	
4. TITLE AND SUBTITLE Use of p53 Mutation Analysis for Staging Breast Cancer			5. FUNDING NUMBERS DAMD17-96-1-6170	
6. AUTHOR(S) Marga White, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) OncorMed, Incorporated Gaithersburg, Maryland 20877			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES			19981210 098	
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words)				
14. SUBJECT TERMS Breast Cancer			15. NUMBER OF PAGES 10	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

_____ Where copyrighted material is quoted, permission has been obtained to use such material.

_____ Where material from documents designated for limited distribution quoted, permission has been obtained to use the material.

_____ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.


_____ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

☒ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

_____ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

_____ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

_____ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

 8/31/98

PI - Signature Date

TABLE OF CONTENTS

PART 1.

SF 298 Report Documentation Page **Pg. 2**

PART 2.

Foreword **Pg. 3**

PART 3.

Table of Contents **Pg. 4**

PART 4.

Introduction, Body and Conclusions **Pg. 5**

PART 5.

Summary of Work on Samples **Pg. 6**

Attachments

Personnel/Voucher History

"Use of p53 Mutation Analysis For Staging Breast Cancer"

Final Report

Introduction, Body and Conclusion

This grant began with a collaboration between Oncormed and Dr. Timothy O'Leary from the Department of the Army. Dr. O'Leary was to provide the samples for the evaluation of the Molecular Staging Assay and its applications for detection of micrometastasis in breast cancer. The samples Dr. O'Leary provided were from a retrospective study. When these samples were collected, the protocols in use at the time were not compatible with retaining the genetic material intact. As a result, the DNA that was isolated to perform the Molecular Staging Assay was quite degraded. Oncormed extended a great deal of energy in attempts to salvage DNA of sufficient quality and quantity from these samples to do the study without success (see report from ?).

After it was decided that Dr. O'Leary's samples could not be used to complete this study, another collaborator was identified. Dr. Bruce Ponder from ? had 100 samples from breast cancer patients that could be used to complete this study. An initial evaluation of the samples indicated they were of sufficient quality and quantity. The work was initiated on these samples and a summary of the progress is attached.

Over the past several months, the focus of Oncormed has been changed. Our Director of Scientific Affairs, Dr. Christine Carter, left the company in the summer of 1997 and our Grants Department was eliminated. I then took over as Principal Investigator. However, over the past year I and my department have been forced to place the majority of the resources on basic business considerations related to the survival of the company. This has now culminated in the acquisition of Oncormed by another biotechnology company, Gene Logic. As a result of this purchase all current on-going projects at Oncormed have been evaluated for their compatibility with the goals of the new combined entity. It has been decided that this project does not fit into the goals of Gene Logic.

It is a great disappointment to myself and the Oncormed staff that we will be unable to complete this study. We hope that the unused portion of the funding can be redirected to other worthy studies.

**“Use of p53 Mutation Analysis For Staging Breast Cancer”
Final Report**

Summary of Work on Army Grant Samples

The following is a brief summary of the various stages of sample processing the Army Grant samples have been through as of April, 1998:

Stage I.	<u>DNA</u>
<u>Extraction from Paraffin Embedded Samples (slides).</u>	

50

paraffin samples (5 slides / samples or 250 slides) were scrapped from slides for DNA extraction.

Stage II.	<u>PCR</u>
<u>Amplification using p53 primers for exons 5, - 9.</u>	

266

PCR reactions were conducted on the above mentioned DNA samples.

Samples were analyzed on three, large 1.2% agarose gels.

Stage III	<u>PCR</u>
<u>Purification of amplified samples.</u>	

Samples are currently being purified for dye attachment -sequencing reaction to verify the presence or absence of p53 mutations.

Stage IV	<u>Dye -</u>
<u>Attachment / Sequencing Reaction. *(present status)</u>	

Samples that have been successfully amplified by PCR and purified will undergo dye - attachment.

The project was canceled and at the time of cancellation, samples were being prepared for dye attachment. Samples that had been dye-attached but had unsuccessful runs were slated for re-attachment however due to the cancellation of the project these samples were never re-dye attached. The remaining paraffin samples were sent back to Cambridge along with the DNA that was isolated from these paraffin samples. PCR fragments were not mailed because of quality

concerns due to freeze/thaw procedures involving samples diluted in water as opposed to TE buffer.

**PUBLIC VOUCHER FOR PURCHASES AND
SERVICES OTHER THAN PERSONAL**

Continuation Sheet

Voucher # 1
Sheet No. 1

U.S. Department, Bureau, or Establishment:
U.S. Army Medical Research Acquisition Activity

Oncormed, Inc.
Contract No. DAMD17-96-1-6170

Reimbursable costs from 8/1/97 thru 4/30/98

<u>Direct Costs</u>	<u>Amount billed for current period</u>	<u>Cumulative amount from inception to date of this billing</u>
Salaries	\$3,840	\$10,405
Fringe Benefits	\$511	\$1,384
Travel	\$0	\$1,042
Supplies	\$692	\$5,675
Subcontract	\$0	\$120
Other	\$0	\$0
Equipment	\$0	\$0
Total Direct Costs	\$5,043	\$18,626
<u>Indirect Costs</u>		
Indirect Cost (60% of Labor + Fringe)	\$2,611	\$7,074
G&A Cost (10% of All Cost)	\$765	\$2,570
Total Indirect Costs	\$3,376	\$9,644
Total Amount Claimed	\$8,419	\$28,270

**PUBLIC VOUCHER FOR PURCHASES AND
SERVICES OTHER THAN PERSONAL**

Continuation Sheet

Voucher # 1
Sheet No. 2

U.S. Department, Bureau, or Establishment:
U.S. Army Medical Research Acquisition Activity

Oncormed, Inc.
Contract No. DAMD17-96-1-6170

Reimbursable costs from 8/1/97 thru 4/30/98

<u>Direct Costs</u>	<u>Amount billed for current period</u>	<u>Cumulative amount from inception to date of this billing</u>
<u>Salaries</u>	\$3,840	\$10,405
<u>Travel</u>		
Transporation	\$0	\$286
Loding	\$0	\$626
Meals	\$0	\$130
Total Travel Costs	\$0	\$1,042
<u>Supplies</u>		
Paraffin/DNA preparation reagents	\$250	\$850
PCR amplification reagents	\$442	\$4,042
Barrier pipet tips	\$0	\$300
Camera film	\$0	\$30
Laboratory disposables	\$0	\$453
Total Supplies Costs	\$692	\$5675

**PUBLIC VOUCHER FOR PURCHASES AND
SERVICES OTHER THAN PERSONAL**

Continuation Sheet

Voucher # 1
Sheet No. 3

U.S. Department, Bureau, or Establishment:
U.S. Army Medical Research Acquisition Activity

Oncormed, Inc.
Contract No. DAMD17-96-1-6170

Reimbursable costs from 8/1/97 thru 4/30/98

<u>Direct Costs</u>	<u>Amount billed for current period</u>	<u>Cumulative amount from inception to date of this billing</u>
<u>Subcontract</u>		
Consultant came to Oncormed to demonstrate testing procedure in the laboratory	\$0	\$120
Total Subcontract Costs	\$0	\$120
<u>Fringe Benefits</u>		
13.30% of labor	\$511	\$1,384
<u>Indirect Costs</u>		
60% of labor + fringe	\$2,611	\$7,074
<u>G&A Cost</u>		
10% of all costs	\$765	\$2,570
Total Amount Claimed	\$8,419	\$28,270